Phase II KEYNOTE 158: Pembrolizumab in Advanced Small-Cell Lung Cancer

June 1-5, 2018; Chicago, Illinois
Pembrolizumab showed promising antitumor activity in patients with SCLC, particularly those with PD-L1–positive tumors.
Format: Microsoft PowerPoint (.ppt)
File Size: 220 KB
Released: June 13, 2018

Acknowledgements

Jointly provided by Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
Astellas
AstraZeneca
Celgene Corporation
Eisai
Genentech
Janssen Therapeutics
Merck & Co., Inc.
Seattle Genetics

Related Content

Commentary on management challenges and incorporating novel therapies for gynecologic cancers, from Clinical Care Options (CCO)

David Scott Miller, MD, FACOG, FACS Angeles Alvarez Secord, MD, MHSc Released: May 23, 2022

Downloadable slideset updated with highlights of key gynecologic oncology studies presented at conferences throughout 2022, from Clinical Care Options (CCO)

David Scott Miller, MD, FACOG, FACS Angeles Alvarez Secord, MD, MHSc Released: May 20, 2022

Clinical Care Options (CCO) commentary: Joel Neal, MD, discusses management of non-small-cell lung cancer (NSCLC) with uncommon EGFR mutations

Joel W. Neal, MD, PhD Released: May 20, 2022

Podcast episode with expert insights on new data from SGO 2022 in endometrial, ovarian, and cervical cancers, from Clinical Care Options (CCO)

David Scott Miller, MD, FACOG, FACS Angeles Alvarez Secord, MD, MHSc Released: May 19, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings